Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The toll-like receptor 2/4 (TLR2/4) signalling pathway presents a dual role in anti-tumour therapy, acting as both an immune stimulant (agonists) and a therapeutic target (antagonists) in chronic inflammation.
• Blocking TLR2/4 signalling is a potential strategy to improve patient prognosis, especially in cases of post-surgical cancer proliferation and metastasis.

Purpose of the Study:

• To develop a novel small-molecule co-inhibitor targeting the TLR2/4 signalling pathway for anti-tumour therapy.
• To evaluate the efficacy of the developed inhibitor in preclinical models.

Main Methods:

• High-throughput screening of 14,400 small molecules to identify potential inhibitors.
• Hit-to-lead structural optimization to obtain the final compound, TX-33.
• Assessment of TX-33's inhibitory effects on pro-inflammatory cytokines in RAW264.7 cells and its efficacy in anti-tumour experiments.

Main Results:

• The small molecule TX-33 was identified as an effective inhibitor of the TLR2/4 signalling pathways.
• TX-33 significantly suppressed the release of multiple pro-inflammatory cytokines from RAW264.7 cells.
• TX-33 demonstrated promising efficacy in subsequent anti-tumour experiments.

Conclusions:

• The study provides a novel understanding of TLR2/4's role in cancer development and progression.
• TX-33 represents a novel therapeutic strategy for anti-tumour therapy, particularly by targeting the TLR2/4 pathway.